Human Monoclonal Antibodies: Methods and Protocols

486 Pages·2019·11.1 MB·English

by  Michael Steinitz

Methods in
Molecular Biology 1904
Michael Steinitz Editor
Human
Monoclonal
Antibodies
Methods and Protocols
Second Edition
M M B
ETHODS IN OLECULAR IO LO GY
SeriesEditor
JohnM.Walker
School of Lifeand MedicalSciences
University ofHertfordshire
Hatfield, Hertfordshire,AL109AB,UK
Forfurther volumes:
http://www.springer.com/series/7651
Human Monoclonal Antibodies
Methods and Protocols
Second Edition
Edited by
Michael Steinitz
Department of Pathology, The Hebrew University, Hadassah Medical School, Jerusalem, Israel
Editor
MichaelSteinitz
DepartmentofPathology
TheHebrewUniversity
HadassahMedicalSchool
Jerusalem,Israel
ISSN1064-3745 ISSN1940-6029 (electronic)
MethodsinMolecularBiology
ISBN978-1-4939-8957-7 ISBN978-1-4939-8958-4 (eBook)
https://doi.org/10.1007/978-1-4939-8958-4
LibraryofCongressControlNumber:2018964050
©SpringerScience+BusinessMedia,LLC,partofSpringerNature2019
Thisworkissubjecttocopyright.AllrightsarereservedbythePublisher,whetherthewholeorpartofthematerialis
concerned,specificallytherightsoftranslation,reprinting,reuseofillustrations,recitation,broadcasting,reproduction
onmicrofilmsorinanyotherphysicalway,andtransmissionorinformationstorageandretrieval,electronicadaptation,
computersoftware,orbysimilarordissimilarmethodologynowknownorhereafterdeveloped.
Theuseofgeneraldescriptivenames,registerednames,trademarks,servicemarks,etc.inthispublicationdoesnotimply,
evenintheabsenceofaspecificstatement,thatsuchnamesareexemptfromtherelevantprotectivelawsandregulations
andthereforefreeforgeneraluse.
Thepublisher,theauthors,andtheeditorsaresafetoassumethattheadviceandinformationinthisbookarebelievedto
betrueandaccurateatthedateofpublication.Neitherthepublishernortheauthorsortheeditorsgiveawarranty,
expressorimplied,withrespecttothematerialcontainedhereinorforanyerrorsoromissionsthatmayhavebeenmade.
Thepublisherremainsneutralwithregardtojurisdictionalclaimsinpublishedmapsandinstitutionalaffiliations.
This Humana Press imprint is published by the registered company Springer Science+Business Media, LLC, part of
SpringerNature.
Theregisteredcompanyaddressis:233SpringStreet,NewYork,NY10013,U.S.A.
Dedication
This book is dedicated to George Klein, 1925–2016, a giant creative and stimulating
scientistofinfinite knowledge,friend,and mentor.Hislegacy isanever-fadinglighthouse
tohundredsof formerstudents,co-workers,colleagues,andfriends.
v
Preface
A second edition of Springer Protocols book Human Monoclonal Antibodies is a natural
outcomeoftherapiddevelopmentsintheareaandtheremarkableinterestattractedbyour
2014firsteditionofthebook.
Itisamazingwhatarapidanddramaticdevelopmenthasoccurredinthefieldofhuman
monoclonalantibodiessincethefirsttimethesewereproducedinthelaboratory.Itwasthe
pioneeringstudyinitiatedbyProfessorGeorgeKleininStockholmin1977[1]thatshowed
the feasibility of making such antibodies from immortalized peripheral blood antigen-
committedhumanBlymphocytes.
Theextensivebasicimmuneresearchwhichhastakenplaceduringthelastyearsrapidly
convergedintotheclinic.TheFastanddramaticdevelopmentofnovelimmunetreatments
intheclinicusinghumanmonoclonalantibodiesurgedtheimprovementsoftraditionaland
alsocompletelynewtechniquesinvolvedintheproductionoftheantibodies.Theintroduc-
tion of monoclonal antibodies directed against lymphocyte cell-surface costimulatory/
immune checkpoint receptors that mediate the immune response has been revolutionary.
These antibodies enable overcome immune unresponsiveness (i.e., tolerance) of T cells.
Antibodies against costimulatory lymphocyte receptors which now are used in the clinic
provedverybeneficialfor tumorpatientsatleastinrelationtosometypesofcancer.
Continuousprogressinmoleculartechniquesenablesgenuinemanagementofantibody
molecules. Such reagents introduced into cytotoxic T cells promise new horizons for the
treatmentofcancerpatients.
The present Springer Protocols book reflects some of the recent developments in the
area.Itincludesseveralcompletelynewchaptersrelatedtotopicsthatwerenotdiscussedin
thefirstedition.Inaddition,somechaptersfromthefirsteditionareupdatedwithnecessary
revisions.Similar tothefirstedition, besidesthedetailedspecifictechnicalprotocols, there
areafewreviewmanuscriptstoo.
Jerusalem,Israel MichaelSteinitz
Reference
1. Steinitz M, Klein G, Koskimies S, Ma¨kela¨ O (1977) EBV virus induced B lymphocyte cell lines
producingspecificantibody.Nature269:420–422
vii
Contents
Preface ..................................................................... vii
Contributors................................................................. xi
1 HumanMonoclonalAntibodies:TheBenefitsofHumanization.............. 1
HermanWaldmann
2 CancerImmunotherapy:TheDawnofAntibodyCocktails................... 11
IlariaMarrocco,DonatellaRomaniello,andYosefYarden
3 IgMNaturalAutoantibodiesinPhysiologyandtheTreatmentofDisease...... 53
MahboobehFereidan-Esfahani,TarekNayfeh,ArthurWarrington,
CharlesL.Howe,andMosesRodriguez
4 MonoclonalAntibodiesfor theTreatmentofMelanoma:Present
andFutureStrategies.................................................... 83
MadhuriBhandaruandAnandRotte
5 AnEfficientMethodtoGenerateMonoclonalAntibodies
fromHumanBCells .................................................... 109
JennaJ.Guthmiller,HaleyL.Dugan,KarlynnE.Neu,
LindaYu-LingLan,andPatrickC.Wilson
6 IsolationofAntigen-Specific,Antibody-SecretingCells
UsingaChip-BasedImmunospotArray ................................... 147
HiroyukiKishi,TatsuhikoOzawa,HiroshiHamana,
EijiKobayashi,andAtsushiMuraguchi
7 PurificationofHumanMonoclonalAntibodiesandTheirFragments.......... 163
NicoleUlmer,SebastianVogg,ThomasMu¨ller-Spa¨th,
andMassimoMorbidelli
8 One-TubeMulticolorFlowCytometryAssay(OTMA)
forComprehensiveImmunophenotypingofPeripheralBlood................ 189
Anna-JasminaDonaubauer,PaulF.Ru¨hle,InaBecker,
RainerFietkau,UdoS.Gaipl,andBenjaminFrey
9 HumanizationandSimultaneousOptimizationofMonoclonalAntibody...... 213
TaichiKuramochi,TomoyukiIgawa,HiroyukiTsunoda,
andKunihiroHattori
10 AntibodyFragmentsHumanization:BeginningwiththeEndinMind ........ 231
NicolasAubreyandPhilippeBilliald
11 Antigen-SpecificHumanMonoclonalAntibodies
fromTransgenicMice ................................................... 253
SusanaMagada´nMomp(cid:1)o andA´fricaGonza´lez-Ferna´ndez
12 RefiningtheQualityofMonoclonalAntibodies:Grafting
UniquePeptide-BindingSiteintheFabFramework ........................ 293
JeremyD.KingandJohnC.Williams
13 BasicProceduresforDetectionandCytotoxicityofChimeric
AntigenReceptors ...................................................... 299
Keichiro Mihara,TetsumiYoshida,andJoyeetaBhattacharyya
ix
x Contents
14 RapidChimerizationofAntibodies ....................................... 307
KojiHashimoto,KoheiKurosawa,HidetakaSeo,andKunihiroOhta
15 PhageDisplayTechnologyforHumanMonoclonalAntibodies............... 319
MarcoDalFerro,SerenaRizzo,EmanuelaRizzo,
FrancescaMarano,ImmacolataLuisi,OlgaTarasiuk,
andDanieleSblattero
16 RecombinantAntibodySelectionsbyCombiningPhage
andYeastDisplay ....................................................... 339
FortunatoFerrara,MariaFeliciaSoluri,andDanieleSblattero
17 EpitopeMappingviaPhageDisplayfromSingle-GeneLibraries.............. 353
ViolaFu¨hner,PhilipAlexanderHeine,KilianJohannesCarlZilkens,
DorisMeier,KristianDanielRalphRoth,
GustavoMarc¸alSchmidtGarciaMoreira,MichaelHust,
andGiulioRusso
18 AHigh-ThroughputMagneticNanoparticle-BasedSemi-Automated
AntibodyPhageDisplayBiopanning ...................................... 377
AngelaChiewWenCh’ng,AzimahAhmad,Zolta´nKonthur,
andTheamSoonLim
19 ABindingPotencyAssayforPritumumabandEcto-DomainVimentin........ 401
IvanBabic,SantoshKesari,andMarkC.Glassy
20 AMethodtoDetecttheBindingofHyper-GlycosylatedFragment
Crystallizable(Fc)RegionofHumanIgG1toGlycanReceptors ............. 417
PatriciaBlundellandRichardPleass
21 ACell-BasedReporterAssayMeasuringtheActivation
ofFcGammaReceptorsInducedbyTherapeuticMonoclonalAntibodies ..... 423
MichihikoAoyama,MinoruTada,andAkikoIshii-Watabe
22 “BIClonals”:ProductionofBispecificAntibodiesinIgGFormat
inTransientlyTransfectedMammalianCells................................ 431
DanaLitvak-Greenfeld,LilachVaks,StavDror,LimorNahary,
andItaiBenhar
23 ProductionofStabilizedAntibodyFragmentsintheE.coli
BacterialCytoplasmandinTransientlyTransfectedMammalianCells ......... 455
RacheliBirnboim-Perach,YehuditGrinberg,LilachVaks,
LimorNahary,andItaiBenhar
Index ...................................................................... 481
Contributors
AZIMAHAHMAD (cid:1) InstituteforResearchinMolecularMedicine,UniversitiSainsMalaysia,
Penang,Malaysia
MICHIHIKOAOYAMA (cid:1) DivisionofBiologicalChemistryandBiologicals,NationalInstituteof
HealthSciences,Kawasaki,Kanagawa,Japan
NICOLAS AUBREY (cid:1) UMRUniversite´-INRAISP1282,BioMAP,Universite´deTours,Tours,
France
IVANBABIC (cid:1) DepartmentofTranslationalNeurosciencesandNeurotherapeutics,John
WayneCancerInstitute,SantaMonica,CA,USA
INABECKER (cid:1) DepartmentofRadiationOncology,Universita¨tsklinikumErlangen,
Friedrich-Alexander-Universita¨tErlangen-Nu¨rnberg,Erlangen,Germany
ITAIBENHAR (cid:1) SchoolofMolecularCellBiologyandBiotechnology,TheGeorgeS.WiseFaculty
ofLifeSciences,Tel-AvivUniversity,RamatAviv,Israel
MADHURIBHANDARU (cid:1) DepartmentofDermatologyandSkinScience,UniversityofBritish
Columbia,Vancouver,BC,Canada
JOYEETABHATTACHARYYA (cid:1) DepartmentofCardiacResearch,CumballaHillHospitaland
HeartInstitute,Mumbai,India
PHILIPPEBILLIALD (cid:1) SchoolofPharmacy,Paris-SudUniversity,Chaˆtenay-Malabry,France
RACHELIBIRNBOIM-PERACH (cid:1) SchoolofMolecularCellBiologyandBiotechnology,TheGeorge
S.WiseFacultyofLifeSciences,Tel-AvivUniversity,RamatAviv,Israel
PATRICIABLUNDELL (cid:1) LiverpoolSchoolofTropicalMedicine,Liverpool,UK
ANGELACHIEWWENCH’NG (cid:1) InstituteforResearchinMolecularMedicine,UniversitiSains
Malaysia,Penang,Malaysia
MARCODALFERRO (cid:1) DepartmentofLifeSciences,UniversityofTrieste,Trieste,Italy
ANNA-JASMINADONAUBAUER (cid:1) DepartmentofRadiationOncology,Universita¨tsklinikum
Erlangen,Friedrich-Alexander-Universita¨tErlangen-Nu¨rnberg,Erlangen,Germany
STAVDROR (cid:1) SchoolofMolecularCellBiologyandBiotechnology,TheGeorgeS.WiseFacultyof
LifeSciences,Tel-AvivUniversity,RamatAviv,Israel
HALEYL.DUGAN (cid:1) CommitteeonImmunology,UniversityofChicago,Chicago,IL,USA
MAHBOOBEHFEREIDAN-ESFAHANI (cid:1) DepartmentofNeurology,MayoClinic,Rochester,MN,
USA
FORTUNATOFERRARA (cid:1) SpecificaInc.,SantaFe,NM,USA
RAINERFIETKAU (cid:1) DepartmentofRadiationOncology,Universita¨tsklinikumErlangen,
Friedrich-Alexander-Universita¨tErlangen-Nu¨rnberg,Erlangen,Germany
BENJAMINFREY (cid:1) DepartmentofRadiationOncology,Universita¨tsklinikumErlangen,
Friedrich-Alexander-Universita¨tErlangen-Nu¨rnberg,Erlangen,Germany
VIOLAFU¨HNER (cid:1) AbteilungBiotechnologie,Institutfu¨rBiochemie,Biotechnologieund
Bioinformatik,TechnischeUniversita¨tBraunschweig,Braunschweig,Germany
UDOS.GAIPL (cid:1) DepartmentofRadiationOncology,Universita¨tsklinikumErlangen,
Friedrich-Alexander-Universita¨tErlangen-Nu¨rnberg,Erlangen,Germany
MARKC.GLASSY (cid:1) DepartmentofTranslationalNeurosciencesandNeurotherapeutics,John
WayneCancerInstitute,SantaMonica,CA,USA;TranslationalNeuro-Oncology
Laboratory,UCSDMooresCancerCenter,LaJolla,CA,USA;NascentBiotech,Inc.,San
Diego,CA,USA
xi
xii Contributors
´
AFRICAGONZA´LEZ-FERNA´NDEZ (cid:1) Immunology,CentrodeInvestigacionesBiome´dicas
(CINBIO),CentrodeInvestigaci(cid:1)onSingulardeGalicia,InstitutodeInvestigaci(cid:1)on
SanitariaGaliciaSur,UniversidaddeVigo,Vigo,Spain
YEHUDITGRINBERG (cid:1) SchoolofMolecularCellBiologyandBiotechnology,TheGeorgeS.Wise
FacultyofLifeSciences,Tel-AvivUniversity,RamatAviv,Israel
JENNAJ.GUTHMILLER (cid:1) DepartmentofMedicine,SectionofRheumatology,TheKnapp
Center forLupusandImmunology,UniversityofChicago,Chicago,IL,USA
HIROSHIHAMANA (cid:1) DepartmentofImmunology,GraduateSchoolofMedicineand
PharmaceuticalSciences,UniversityofToyama,Toyama,Japan
KOJIHASHIMOTO (cid:1) DepartmentofLifeSciences,GraduateSchoolofArtsandSciences,The
UniversityofTokyo,Tokyo,Japan
KUNIHIROHATTORI (cid:1) ResearchDivision,ChugaiPharmaceutical,Kamakura,Kanagawa,
Japan
PHILIPALEXANDERHEINE (cid:1) AbteilungBiotechnologie,Institutfu¨rBiochemie,Biotechnologie
undBioinformatik, TechnischeUniversita¨tBraunschweig,Braunschweig,Germany
CHARLESL.HOWE (cid:1) DepartmentofNeurology,MayoClinic,Rochester,MN,USA
MICHAELHUST (cid:1) AbteilungBiotechnologie,Institutfu¨rBiochemie,Biotechnologieund
Bioinformatik,TechnischeUniversita¨tBraunschweig,Braunschweig,Germany
TOMOYUKIIGAWA (cid:1) ChugaiPharmabodyResearchPte.Ltd.,Singapore,Singapore
AKIKOISHII-WATABE (cid:1) DivisionofBiologicalChemistryandBiologicals,NationalInstituteof
HealthSciences,Kawasaki,Kanagawa,Japan
SANTOSHKESARI (cid:1) DepartmentofTranslationalNeurosciencesandNeurotherapeutics,John
WayneCancerInstitute,SantaMonica,CA,USA
JEREMYD.KING (cid:1) DepartmentofMolecularMedicine,BeckmanResearchInstituteatCityof
Hope,Duarte,CA,USA
HIROYUKIKISHI (cid:1) DepartmentofImmunology,GraduateSchoolofMedicineand
PharmaceuticalSciences,UniversityofToyama,Toyama,Japan
EIJIKOBAYASHI (cid:1) DepartmentofImmunology,GraduateSchoolofMedicineand
PharmaceuticalSciences,UniversityofToyama,Toyama,Japan
ZOLTA´NKONTHUR (cid:1) DepartmentofBiomolecularSystems,MaxPlanckInstituteofColloids
andInterfaces,Potsdam,Germany
TAICHI KURAMOCHI (cid:1) ChugaiPharmabodyResearchPte.Ltd.,Singapore,Singapore
KOHEIKUROSAWA (cid:1) DepartmentofLifeSciences,GraduateSchoolofArtsandSciences,The
UniversityofTokyo,Tokyo,Japan
LINDAYU-LINGLAN (cid:1) CommitteeonImmunology,UniversityofChicago,Chicago,IL,USA
THEAMSOONLIM (cid:1) InstituteforResearchinMolecularMedicine,UniversitiSainsMalaysia,
Penang,Malaysia;AnalyticalBiochemistryResearchCentre,UniversitiSainsMalaysia,
Penang,Malaysia
DANALITVAK-GREENFELD (cid:1) SchoolofMolecularCellBiologyandBiotechnology,TheGeorgeS.
WiseFacultyofLifeSciences,Tel-AvivUniversity,RamatAviv,Israel
IMMACOLATALUISI (cid:1) DepartmentofLifeSciences,UniversityofTrieste,Trieste,Italy
SUSANAMAGADA´NMOMPO´ (cid:1) Immunology,CentrodeInvestigacionesBiome´dicas(CINBIO),
CentrodeInvestigaci(cid:1)onSingulardeGalicia,InstitutodeInvestigaci(cid:1)onSanitariaGalicia
Sur,UniversidaddeVigo,Vigo,Spain
FRANCESCAMARANO (cid:1) DepartmentofLifeSciences,UniversityofTrieste,Trieste,Italy
ILARIAMARROCCO (cid:1) DepartmentofBiologicalRegulation,WeizmannInstituteofScience,
Rehovot,Israel